WO2003018082A2 - Local drug delivery system in coronary stents - Google Patents

Local drug delivery system in coronary stents Download PDF

Info

Publication number
WO2003018082A2
WO2003018082A2 PCT/IN2002/000173 IN0200173W WO03018082A2 WO 2003018082 A2 WO2003018082 A2 WO 2003018082A2 IN 0200173 W IN0200173 W IN 0200173W WO 03018082 A2 WO03018082 A2 WO 03018082A2
Authority
WO
WIPO (PCT)
Prior art keywords
coating
ajoene
allicin
composition
poly
Prior art date
Application number
PCT/IN2002/000173
Other languages
French (fr)
Inventor
Nandkishore Managoli
Original Assignee
Sahajanand Biotech Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sahajanand Biotech Private Limited filed Critical Sahajanand Biotech Private Limited
Publication of WO2003018082A2 publication Critical patent/WO2003018082A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Definitions

  • This invention relates to the field of cardiology and, more particularly, to a system for the localised delivery of a drug for use following coronary angioplasty or stenting.
  • the invention provides a stent, or other implantable medical device, which has a coating that contains ajoene and/or allicin.
  • Ajoene and allicin are derived from garlic and have been found to be effective in the prevention or inhibition of restenosis following angioplasty.
  • interventional cardiologists deal with the coronary vessels in disease, they are faced with the unenviable task of handling stenosed blood vessels with small diametric lumina, narrowed further by atherosclerotic plaques and vasospasm, leading to near- total, or total blockage of the arteries.
  • Cardiac intervention in such cases in the form of coronary angioplasty or stenting, causes endothelial damage leading to thrombosis, inflammation, proliferation and remodelling of the vasculature.
  • Such selective coagulation inhibitors or anticoagulants and antiproliferative drugs or agents have been isolated from biological sources, such as animals and plants, or have been synthesized in the laboratory in the past few years.
  • the latest advance in pharmacology namely the local drug delivery technique, where drug molecules are packaged with polymers or are bonded to the surface of a device by using biologically derived materials, such as serum, and delivered at the desired site by using a "time-release technique" (i.e. to achieve sustained release of the drug in a controlled manner over a predetermined and prolonged period of time), is nvisaged as the ideal method to locally manage the restenosis problem.
  • Ste s are tubular structures that are implanted within blood vessels and other passageways within the human or animal body for the purpose of treating disease conditions such as aneurysms, occlusions and stenosis. They function to physically support and, if necessary, expand the wall of the blood vessel or other passageway into which they have been implanted.
  • Stents can have either solid or lattice-like walls and may be either self-expandable or expanded by means of inflating a balloon positioned within them.
  • Stents and other implantable medical devices are also commonly used to carry and deliver therapeutic substances, such as anticoagulants, antiplatelet agents and cytostatic agents. These therapeutic substances are often carried in a polymer coating on the stent and then released over a period of time once it has been implanted in the blood vessel or other passageway.
  • US Patent Nos. 5994341, 5869127, 6168619, 6179817, 6203551, 6231600, 6254632, 6258121 and 6280411 describe stents and other implantable medical devices which may have a biocompatible polymeric coating that contains a therapeutic agent.
  • Garlic Allium sativum has been used in traditional medicine for thousands of years; for example, for the prevention of strokes, coronary thrombosis and atherosclerosis, as well as for the treatment of various infectious diseases and vascular disorders.
  • Some components of garlic are known to have antibiotic properties, while others are potent inhibitors of platelet aggregation (one of the initial stages of blood clot formation or thrombosis).
  • US Patent No. 4917921 teaches the combination of a component of garlic called dithiin (a monomeric organosulphur compound that has antibiotic and antithrombogenic properties) with a biocompatible polymer, and the use of the resulting composition in a method for coating polymeric articles.
  • the invention resulted from the finding that ajoene and allicin, which are two components of garlic, have antithrombotic, antibiotic, antiinflammatory and antiproliferative properties and are effective (both individually and together) for preventing or inhibiting restenosis.
  • an implantable medical device such as a stent, comprising a substrate and a biocompatible polymeric coating which covers at least a portion of the said substrate, and wherein the coating contains ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof.
  • the present invention provides a composition which comprises one or more biocompatible polymers and ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof and which is suitable for use in coating an implantable medical device.
  • the present invention still further provides a method of manufacturing an implantable medical device which includes the step of applying such a composition as a coating to the said device.
  • the coating of the stent or other implantable medical device typically contains a total of from 50 to 800 micrograms of the drug or active ingredient (i.e. of ajoene alone, allicin alone or ajoene and allicin in combination).
  • the composition of the coating typically comprises from 60 to 80% by weight of the polymer (preferably 70%) and from 20 to 40%) by weight of the drug (preferably 30%).
  • the invention also provides a method of manufacturing an implantable medical device which comprises applying to a substrate a coating of a composition.
  • the composition may be prepared as a solution of ajoene and/or allicin with biodegradable and biocompatible polymers selected from lactone-based polyesters or copolyesters such as polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides, poly-aminoacids, polysaccharides; polyphosphazenes; poly (ether-ester) copolymers, or blends thereof in a solovent selected from dichloromethane. Dimethyl formamide, dimethyl sulphoxide, hexafluoroisopropanol or acetone.
  • the polymer may be non- absorbable and biocompatible.
  • the polymers are such as polydimethylsiloxane; poly (ethylene-vinylacetate); acrylate based polymers or copolymers, poly (hydroxyethyl methylmethacrylate, polyvinyl pyrrolidone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.
  • the implantable medical devices of this invention include tubular scaffolding bodies, grafts, catheters and, in particular, endoluminal stents (including cardiovascular stents) designed for dealing with various intraluminal occlusions and contractions within the body.
  • the substrate referred to above is thus typically a stent body and which may be made of, for example, metal or a polymer composition.
  • the biocompatible polymeric coating has a composition which permits the ajoene and/or allicin to be controllably released in a predetermined manner over a prolonged period of time. It will be appreciated that its precise composition will be chosen to produce the desired release profile.
  • the polymeric coating may be either biodegradable or non-biodegradable. It may consist of either a single biocompatible polymer or a combination of two or more such materials.
  • the coating comprises polyactides, polyglycolides, polycaprolactone, polydioxanone, polygluconate, polyanhydrides, polyphosphoesters, polyethyleneterpthalate, polyhydroxylbutyrate, polyphosphazene, polyorthoesters or polyphosphate esters, or mixtures or copolymers thereof.
  • the ajoene and/or allicin is disposed, dispersed, dissolved, embedded, micro- encapsulated or otherwise incorporated in the coating or a part of the coating.
  • the coating may comprise two or more layers and which each contain one or both of these components. It will be appreciated that its precise composition will be chosen to produce the desired release profile.
  • the ideal agent(s) for the management of coronary restenosis would have the following properties:
  • antithrombotic and antiplatelet activity to control the amount of thrombus formation and also to control the process of intimal regeneration, which will prevent restenosis
  • antilipemic and antiatherosclerotic activity which act to maintain the potency of the vascular lumen in hyperlipidemic patients and also to improve blood flow by reducing plasma viscosity (blood-thinning property);
  • antiproliferative activity to control neointimal hyperplasia
  • antiseptic activity which may be useful in taking care of any infection introduced during the invasive procedure of angioplasty or coronary stenting
  • Ajoene (from "ajo", Spanish for garlic) is a sulphur-containing natural product derived from the ubiquitous and perennial bulbous herb, Allium sativum. Garlic contains 33 sulphur compounds, the chief one being allicin (diallyl thiosulphonate) which is formed only when garlic is cut or macerated or heated. This is the compound responsible for the offensive odour of garlic. Ajoene is formed by the combination of three molecules of allicin.
  • Ajoene is (E,Z) 4, 5, 9 - trithiadodeca -1, 6, 11 -triene-9-oxide) and has the following structural formula:-
  • E-ajoene Allicin is S-allyl-2-propenethiosulphinate and has the following structural formula:
  • Ajoene and a precursor thereof can be isolated from extracts of garlic. As the garlic is crushed, allicin in the garlic comes into contact with allinase in the cell wall to form allicin. In the presence of a polar molecule (such as a lower alcohol) or even water, allicin forms ajoene.
  • a polar molecule such as a lower alcohol
  • Antithrombotic, antiinflammatory and antiplatelet activity This effect is achieved by interfering with cyclo-oxygenase mediated thromboxane synthesis (a potential stimulant) non-competitively and irreversibly. It inhibits prostaglandin synthetase and lipoxygenase, decreasing thromboxane synthesis and inflammatory cytokines. It also reversibly inhibits platelet aggregation. Ajoene synergistically potentiates the anti- aggregatory action of prostacyclin, indomethacin and dipyridamole. It causes fibrinolysis by inhibiting thromboxane synthesis. These effects lead to reduced thrombus formation and inflammation in the damaged vasculature.
  • Ajoene has been proved to possess antibacterial activity against gram-positive bacteria (such as Bacillus cereus, Bacillus subtilis, Mycobacterium smegmatis, Streptomyces griseus, Straphylococcus aureus and Lactobacillus plantarum) and gram-negative bacteria (like Escherichia coli, Klebsiella pneumoniae and Xanthmonas maltophilia); ajoene also inhibited yeast growth.
  • gram-positive bacteria such as Bacillus cereus, Bacillus subtilis, Mycobacterium smegmatis, Streptomyces griseus, Straphylococcus aureus and Lactobacillus plantarum
  • gram-negative bacteria like Escherichia coli, Klebsiella pneumoniae and Xanthmonas maltophilia
  • Garlic is an abundantly used herb across the globe for culinary as well as medicinal purposes. Garlic and its derivatives are on the Food and Drug Administration's Generally Recognised as Safe (GRAS) list, but it is known to cause gastric irritation if taken in high doses. This effect is not expected to occur when it is administered locally at the site of endothelial injury. Chronic toxicity with garlic and its extracts is unknown. In fact it appears to protect against agents with known genotoxicity, embryotoxicity and carcinogenicity.
  • GRAS Food and Drug Administration's Generally Recognised as Safe
  • Acute and chronic complications following coronary stenting can be reduced by using the safe and multipotential garlic extract, ajoene, which has been proved by in-vitro and in-vivo studies to possess all the beneficial qualities required for countering the processes of thrombus formation, hyperlipemia, atherosclerosis, inflammation, proliferation and sepsis.
  • a coronary stent can be loaded with a drug-polymer complex of a combination of a polymer and ajoene and/or allicin and their derivatives to provide for "time-release".
  • the polymer acts as a vehicle to hold the drug and present it to the site of injury whenever required and as programmed for time-release. The released drug is then able to act locally and counter the acute and chronic complications of coronary stenting which lead to restenosis.
  • Example 1 describes the preparation of a stent with a coating containing ajoene. A coating containing allicin or both ajoene and allicin would be prepared in a corresponding manner.
  • Example 2 demonstrates the time-release properties of the drug from the coating of a stent according to the present invention.
  • Pre-Treatment Received bare stents are given an ultrasonic isopropanol washing treatment for about 30 minutes to 1 hour for better adhesion of the coating material. After that the stents are washed with sterile water and then dried with a hot air drier.
  • a solution of ajoene (the drug) is prepared in a solvent such as dichloromethane, dimethyl formamide, dimethyl sulfoxide, hexafluoroisopropanol or acetone and biodegradable and biocompatible polymers, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides; poly-aminoacids; polysaccharides; polyphosphazenes; poly (ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof.
  • Non-absorbable biocompatible polymers are also suitable candidates.
  • the base coat is from 40% to 45% of the drug; about 250 micro grams of the coating.
  • the second coat can be from 25%) to 30% of the drug; about 210 micrograms of the coating.
  • the third coat contains 30%> to 35%) of the drug; about 240 micrograms of coating in its layer, using a broad band ultrasonic generator attached to a nozzle and medical grade nitrogen gas as the carrier.
  • the power at which the system is operated is 5.0 m Watts.
  • the flow rate is adjusted to about 0.3 ml/min.
  • the spray system is placed in a vacuum amber coloured glass box to eliminate air current and to slow down the evaporation.
  • the stents are positioned (horizontally) 1.5 to 5.0 cm distance from the nozzle and have a dwell time in the spray cloud of about 50 to 60 seconds. The interval is of 10 to 20 seconds and the stent motion is both clockwise and anticlockwise.
  • the room temperature is maintained at 20°C to 23°C.
  • the stent is then dried in ambient conditions for 12 to 16 hours at 38°C. Then the drug-coated stent is stored in a sealed container.
  • EXAMPLE 2 EXAMPLE 2
  • IP pH 7.5 phosphate buffer saline
  • Drug concentrations are determined by extraction into 2 ml DCM followed by evaporation to dryness under a stream of medical grade nitrogen gas, reconstitution in 1 ml of acetonitrile in water and analysis using the HPLC method. 30%> of the drug is released initially in 2 to 3 days, 21.5% of the drug is released within the next 7 to 10 days and the remaining 42.5% should be released in the next 35 to 40 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention provides an implantable medical device comprising a substrate and a biocompatible polymeric coating which covers at least a portion of the said substrate, and wherein the coating contains ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof, a composition comprising biocompatible polymer/s and ajoene and/or allicin suitable for use in coating the implantable medical device.

Description

LOCAL DRUG DELIVERY SYSTEM IN CORONARY STENTS
Technical field: This invention relates to the field of cardiology and, more particularly, to a system for the localised delivery of a drug for use following coronary angioplasty or stenting. The invention provides a stent, or other implantable medical device, which has a coating that contains ajoene and/or allicin. Ajoene and allicin are derived from garlic and have been found to be effective in the prevention or inhibition of restenosis following angioplasty.
Background:
The field of interventional cardiology has seen radical changes and has metamorphosed into a specialized branch of medicine in recent years. Exciting innovations through research have created myriad arenas where improvements are possible in the existing knowledge about this field of medicine. Researchers have zeroed in on the interface between the blood components (namely, the platelets, the red blood cells and the leukocytes) and the vessel wall as the potential area for research, where a series of physico-chemical events are triggered by vascular injury and that restore the lost anatomy of the vasculature.
When interventional cardiologists deal with the coronary vessels in disease, they are faced with the unenviable task of handling stenosed blood vessels with small diametric lumina, narrowed further by atherosclerotic plaques and vasospasm, leading to near- total, or total blockage of the arteries. Cardiac intervention in such cases, in the form of coronary angioplasty or stenting, causes endothelial damage leading to thrombosis, inflammation, proliferation and remodelling of the vasculature.
In a small percentage of cases (about 3.7%), cardiac intervention is followed by exuberant thrombus formation, or, as a late complication (in about 22% of cases), neointimal hyperplasia (i.e. the overgrowth of the vascular lining endothelium), both of which cause restenosis. The problem of coronary restenosis has been a matter of concern to interventional cardiologists and a great deal of research is being conducted to prevent and/or treat this complication. Several steps in the coagulation cascade as well as the cell cycle are being looked at where they can be blocked to control the process of restenosis. Such selective coagulation inhibitors or anticoagulants and antiproliferative drugs or agents have been isolated from biological sources, such as animals and plants, or have been synthesized in the laboratory in the past few years. Secondly, the latest advance in pharmacology, namely the local drug delivery technique, where drug molecules are packaged with polymers or are bonded to the surface of a device by using biologically derived materials, such as serum, and delivered at the desired site by using a "time-release technique" (i.e. to achieve sustained release of the drug in a controlled manner over a predetermined and prolonged period of time), is nvisaged as the ideal method to locally manage the restenosis problem.
Ste s are tubular structures that are implanted within blood vessels and other passageways within the human or animal body for the purpose of treating disease conditions such as aneurysms, occlusions and stenosis. They function to physically support and, if necessary, expand the wall of the blood vessel or other passageway into which they have been implanted. Stents can have either solid or lattice-like walls and may be either self-expandable or expanded by means of inflating a balloon positioned within them.
Stents and other implantable medical devices are also commonly used to carry and deliver therapeutic substances, such as anticoagulants, antiplatelet agents and cytostatic agents. These therapeutic substances are often carried in a polymer coating on the stent and then released over a period of time once it has been implanted in the blood vessel or other passageway. US Patent Nos. 5994341, 5869127, 6168619, 6179817, 6203551, 6231600, 6254632, 6258121 and 6280411 describe stents and other implantable medical devices which may have a biocompatible polymeric coating that contains a therapeutic agent.
Garlic (Allium sativum) has been used in traditional medicine for thousands of years; for example, for the prevention of strokes, coronary thrombosis and atherosclerosis, as well as for the treatment of various infectious diseases and vascular disorders. Some components of garlic are known to have antibiotic properties, while others are potent inhibitors of platelet aggregation (one of the initial stages of blood clot formation or thrombosis). US Patent No. 4917921 teaches the combination of a component of garlic called dithiin (a monomeric organosulphur compound that has antibiotic and antithrombogenic properties) with a biocompatible polymer, and the use of the resulting composition in a method for coating polymeric articles.
It is an object of the present invention to provide an improved means of preventing or inhibiting restenosis following a stent angioplasty. The invention resulted from the finding that ajoene and allicin, which are two components of garlic, have antithrombotic, antibiotic, antiinflammatory and antiproliferative properties and are effective (both individually and together) for preventing or inhibiting restenosis.
Description of the invention:
According to the present invention there is provided an implantable medical device, such as a stent, comprising a substrate and a biocompatible polymeric coating which covers at least a portion of the said substrate, and wherein the coating contains ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof.
According to a further embodiment, the present invention provides a composition which comprises one or more biocompatible polymers and ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof and which is suitable for use in coating an implantable medical device. The present invention still further provides a method of manufacturing an implantable medical device which includes the step of applying such a composition as a coating to the said device.
The coating of the stent or other implantable medical device typically contains a total of from 50 to 800 micrograms of the drug or active ingredient (i.e. of ajoene alone, allicin alone or ajoene and allicin in combination). The composition of the coating typically comprises from 60 to 80% by weight of the polymer (preferably 70%) and from 20 to 40%) by weight of the drug (preferably 30%).
Thus, the invention also provides a method of manufacturing an implantable medical device which comprises applying to a substrate a coating of a composition. The composition may be prepared as a solution of ajoene and/or allicin with biodegradable and biocompatible polymers selected from lactone-based polyesters or copolyesters such as polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides, poly-aminoacids, polysaccharides; polyphosphazenes; poly (ether-ester) copolymers, or blends thereof in a solovent selected from dichloromethane. Dimethyl formamide, dimethyl sulphoxide, hexafluoroisopropanol or acetone. The polymer may be non- absorbable and biocompatible.
The polymers are such as polydimethylsiloxane; poly (ethylene-vinylacetate); acrylate based polymers or copolymers, poly (hydroxyethyl methylmethacrylate, polyvinyl pyrrolidone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.
The implantable medical devices of this invention include tubular scaffolding bodies, grafts, catheters and, in particular, endoluminal stents (including cardiovascular stents) designed for dealing with various intraluminal occlusions and contractions within the body. The substrate referred to above is thus typically a stent body and which may be made of, for example, metal or a polymer composition.
The biocompatible polymeric coating has a composition which permits the ajoene and/or allicin to be controllably released in a predetermined manner over a prolonged period of time. It will be appreciated that its precise composition will be chosen to produce the desired release profile. The polymeric coating may be either biodegradable or non-biodegradable. It may consist of either a single biocompatible polymer or a combination of two or more such materials. Typically, the coating comprises polyactides, polyglycolides, polycaprolactone, polydioxanone, polygluconate, polyanhydrides, polyphosphoesters, polyethyleneterpthalate, polyhydroxylbutyrate, polyphosphazene, polyorthoesters or polyphosphate esters, or mixtures or copolymers thereof.
The ajoene and/or allicin is disposed, dispersed, dissolved, embedded, micro- encapsulated or otherwise incorporated in the coating or a part of the coating. Furthermore, the coating may comprise two or more layers and which each contain one or both of these components. It will be appreciated that its precise composition will be chosen to produce the desired release profile. The ideal agent(s) for the management of coronary restenosis would have the following properties:
1 ) antithrombotic and antiplatelet activity, to control the amount of thrombus formation and also to control the process of intimal regeneration, which will prevent restenosis; 2) antilipemic and antiatherosclerotic activity, which act to maintain the potency of the vascular lumen in hyperlipidemic patients and also to improve blood flow by reducing plasma viscosity (blood-thinning property);
3) antunflammatory activity, to control the inflammation;
4) antiproliferative activity, to control neointimal hyperplasia; 4) antiseptic activity, which may be useful in taking care of any infection introduced during the invasive procedure of angioplasty or coronary stenting; and
5) safe for use with minimal side effects (local as well as systemic).
It has been found that these multiple beneficial properties are possessed by botanical extracts from the root bulb of the much-studied and commonly used Allium sativum (garlic) called ajoene and allicin.
Ajoene (from "ajo", Spanish for garlic) is a sulphur-containing natural product derived from the ubiquitous and perennial bulbous herb, Allium sativum. Garlic contains 33 sulphur compounds, the chief one being allicin (diallyl thiosulphonate) which is formed only when garlic is cut or macerated or heated. This is the compound responsible for the offensive odour of garlic. Ajoene is formed by the combination of three molecules of allicin.
Ajoene is (E,Z) 4, 5, 9 - trithiadodeca -1, 6, 11 -triene-9-oxide) and has the following structural formula:-
O
II
CH;=CH— CH;— S — CHj — Ctt=CH — S — S — CH; — C.H~ CHj Which can be represented as:-
Figure imgf000007_0001
E-ajoene Allicin is S-allyl-2-propenethiosulphinate and has the following structural formula:
O CHa CU - CH- S - S - CHi - CH - CHa
Ajoene and a precursor thereof can be isolated from extracts of garlic. As the garlic is crushed, allicin in the garlic comes into contact with allinase in the cell wall to form allicin. In the presence of a polar molecule (such as a lower alcohol) or even water, allicin forms ajoene.
Pharmacological actions:
A) Antithrombotic, antiinflammatory and antiplatelet activity: This effect is achieved by interfering with cyclo-oxygenase mediated thromboxane synthesis (a potential stimulant) non-competitively and irreversibly. It inhibits prostaglandin synthetase and lipoxygenase, decreasing thromboxane synthesis and inflammatory cytokines. It also reversibly inhibits platelet aggregation. Ajoene synergistically potentiates the anti- aggregatory action of prostacyclin, indomethacin and dipyridamole. It causes fibrinolysis by inhibiting thromboxane synthesis. These effects lead to reduced thrombus formation and inflammation in the damaged vasculature.
B) Antilipemic and antiatherosclerotic activity: In-vitro animal studies and in-vivo human studies have proved that ajoene is capable of reducing blood cholesterol by up to 10% and favourably altering the HDL/LDL ratios (by increasing the HDL levels and reducing LDL levels). Significant reduction in triglycerides has also been noted following garlic administration. It also exhibits antiatherosclerotic activity by reducing lipid content of existing plaques and by significantly inhibiting the proliferative activity of smooth muscle cells from atherosclerotic plaques. These effects lead to significant improvement in plasma viscosity and capillary blood flow as evidenced by reduction in pulse wave velocity and elastic vascular resistance (two measures of arterial elasticity). Blood pressure also fell by up to 7% due to these effects.
C) Antiseptic activity: Ajoene has been proved to possess antibacterial activity against gram-positive bacteria (such as Bacillus cereus, Bacillus subtilis, Mycobacterium smegmatis, Streptomyces griseus, Straphylococcus aureus and Lactobacillus plantarum) and gram-negative bacteria (like Escherichia coli, Klebsiella pneumoniae and Xanthmonas maltophilia); ajoene also inhibited yeast growth.
D) Safety of use: Garlic is an abundantly used herb across the globe for culinary as well as medicinal purposes. Garlic and its derivatives are on the Food and Drug Administration's Generally Recognised as Safe (GRAS) list, but it is known to cause gastric irritation if taken in high doses. This effect is not expected to occur when it is administered locally at the site of endothelial injury. Chronic toxicity with garlic and its extracts is unknown. In fact it appears to protect against agents with known genotoxicity, embryotoxicity and carcinogenicity.
Acute and chronic complications following coronary stenting can be reduced by using the safe and multipotential garlic extract, ajoene, which has been proved by in-vitro and in-vivo studies to possess all the beneficial qualities required for countering the processes of thrombus formation, hyperlipemia, atherosclerosis, inflammation, proliferation and sepsis. A coronary stent can be loaded with a drug-polymer complex of a combination of a polymer and ajoene and/or allicin and their derivatives to provide for "time-release". The polymer acts as a vehicle to hold the drug and present it to the site of injury whenever required and as programmed for time-release. The released drug is then able to act locally and counter the acute and chronic complications of coronary stenting which lead to restenosis.
The present invention will now be illustrated by the following Examples (all parts are by weight unless otherwise indicated). Example 1 describes the preparation of a stent with a coating containing ajoene. A coating containing allicin or both ajoene and allicin would be prepared in a corresponding manner. Example 2 demonstrates the time-release properties of the drug from the coating of a stent according to the present invention.
EXAMPLE 1
Pre-Treatment: Received bare stents are given an ultrasonic isopropanol washing treatment for about 30 minutes to 1 hour for better adhesion of the coating material. After that the stents are washed with sterile water and then dried with a hot air drier.
Spray coating process: A solution of ajoene (the drug) is prepared in a solvent such as dichloromethane, dimethyl formamide, dimethyl sulfoxide, hexafluoroisopropanol or acetone and biodegradable and biocompatible polymers, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides; poly-aminoacids; polysaccharides; polyphosphazenes; poly (ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof. Non-absorbable biocompatible polymers are also suitable candidates. Polymers such as polydimethylsiloxane; poly (ethylene-vinylacetate); acrylate based polymers or copolymers, e.g., poly (hydroxyethyl methylmethacrylate, polyvinyl pyrrolidone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters could also be used . The base coat is from 40% to 45% of the drug; about 250 micro grams of the coating. The second coat can be from 25%) to 30% of the drug; about 210 micrograms of the coating. The third coat contains 30%> to 35%) of the drug; about 240 micrograms of coating in its layer, using a broad band ultrasonic generator attached to a nozzle and medical grade nitrogen gas as the carrier. The power at which the system is operated is 5.0 m Watts. The flow rate is adjusted to about 0.3 ml/min. The spray system is placed in a vacuum amber coloured glass box to eliminate air current and to slow down the evaporation. The stents are positioned (horizontally) 1.5 to 5.0 cm distance from the nozzle and have a dwell time in the spray cloud of about 50 to 60 seconds. The interval is of 10 to 20 seconds and the stent motion is both clockwise and anticlockwise. The room temperature is maintained at 20°C to 23°C. The stent is then dried in ambient conditions for 12 to 16 hours at 38°C. Then the drug-coated stent is stored in a sealed container. EXAMPLE 2
Drug Release Studies:
Preparation of pH 7.5 phosphate buffer saline (IP) : According to IP procedure. In 15 ml glass, screw-capped tubes are placed 10 ml of 10 mM phosphate buffered saline (PBS), pH 7.4 and 200 micrograms of drug-loaded stent. The tubes are tumbled at 37°C and at given time intervals, centrifuged at 1500 x g for 5 mintues and the supernatant saved for analysis. Drug-loaded stents are resuspended in fresh PBS (10ml) at 37°C and reincubated. Drug concentrations are determined by extraction into 2 ml DCM followed by evaporation to dryness under a stream of medical grade nitrogen gas, reconstitution in 1 ml of acetonitrile in water and analysis using the HPLC method. 30%> of the drug is released initially in 2 to 3 days, 21.5% of the drug is released within the next 7 to 10 days and the remaining 42.5% should be released in the next 35 to 40 days.

Claims

l.An implantable medical device comprising a substrate and a biocompatible polymeric coating which covers at least a portion of the said substrate, and wherein the coating contains ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof.
2. A device as claimed in claim 1, wherein the substrate is a stent body.
3. A device as claimed in claim 1 or claim 2, wherein the composition of the polymeric coating permits the ajoene and/or allicin to be controllably released in a localised and predetermined manner over a prolonged period of time.
4. A device as claimed in any one of the preceding claims, wherein the coating comprises polylactides, polyglycolides, polycaprolactone, polydioxanone, polygluconate, polyanhydrides, polyphosphoesters, polyethyleneterpthalate, polyhydroxylbutyrate, polyphosphazene, polyorthoesters or polyphosphate esters, or mixtures or copolymers thereof.
5.A device as claimed in any one of the preceding claims, wherein the ajoene and/or allicin is disposed, dispersed, dissolved, embedded, microencapsulated or otherwise incorporated in the coating or a part of the coating.
6.A device as claimed in any one of the preceding claims, wherein the coating comprises two or more layers and each of which contain ajoene and/or allicin.
7. A composition comprising biocompatible polymer/s and ajoene and/or allicin or isomers, analogues, homologues or derivatives thereof and which is suitable for use in coating an implantable medical device.
8. A composition as claimed in claim 7 wherein the amount of biocompatible polymer/s is 55-80% and the amount of ajoene and/or allicin, its isomers, analogues, homologues or derivatives is 20 to 45%).
9. A method of manufacturing an implantable medical device which comprises applying to a substrate a coating of a composition as claimed in claim 7.
10. A method as claimed in claim 9 wherein the composition is prepared as a solution of ajoene and/or allicin with biodegradable and biocompatible polymers selected from lactone-based polyesters or copolyesters such as polyactide, polycaprolactone- glycolide, polyorthoesters, polyanhydrides, poly-aminoacids, polysaccharides; polyphosphazenes; poly (ester-ester) copolymers, or blends thereof in a solvent selected from dichloromethane, dimethyl formamide, dimethyl sulphoxide, hexafluoroisopropanol or acetone.
11. A method as claimed in claim 9 wherein the polymer is non-absorbable.
12. A method as claimed in claim 9 wherein the polymers are such as polydimethylsiloxane; poly (ethylene-vinylacetate); acrylate based polymers or copolymers, poly (hydroxyethyl methylmethacrylate, polyvinyl pyrrolidone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.
PCT/IN2002/000173 2001-08-29 2002-08-28 Local drug delivery system in coronary stents WO2003018082A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120887A GB0120887D0 (en) 2001-08-29 2001-08-29 Local drug delivery system in coronary stents
GB0120887.5 2001-08-29

Publications (1)

Publication Number Publication Date
WO2003018082A2 true WO2003018082A2 (en) 2003-03-06

Family

ID=9921134

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2002/003480 WO2003018080A1 (en) 2001-08-29 2002-08-28 Local drug delivery system in coronary stents
PCT/IN2002/000173 WO2003018082A2 (en) 2001-08-29 2002-08-28 Local drug delivery system in coronary stents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003480 WO2003018080A1 (en) 2001-08-29 2002-08-28 Local drug delivery system in coronary stents

Country Status (2)

Country Link
GB (1) GB0120887D0 (en)
WO (2) WO2003018080A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2449264A (en) * 2007-05-15 2008-11-19 Chameleon Biosurfaces Ltd A coated medical device
WO2008139200A3 (en) * 2007-05-15 2009-10-29 Chameleon Biosurfaces Limited Polymer coatings on medical devices
WO2012076016A1 (en) * 2010-12-08 2012-06-14 Danmarks Tekniske Universitet Process for the manufacture of ajoene derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119113230A (en) * 2024-09-14 2024-12-13 广州见微医疗科技有限公司 Antibacterial catheter and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177081B (en) * 1978-12-12 1981-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing the occlusion complex of allicin with cyclodextrin
DE3821964A1 (en) * 1988-06-29 1990-01-11 Biotechnolog Forschung Gmbh USE OF AJOEN AND AJOEN DERIVATIVES AS OR IN CYTOSTATIKA AND / OR CYTOTOXIKA AND A MEDIUM WITH THE COMPOUNDS
JPH04108728A (en) * 1990-08-27 1992-04-09 Kanebo Ltd Microcapsule and fibrous structure
US5824048A (en) * 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
WO1999021008A1 (en) * 1997-10-23 1999-04-29 Pharmaprint, Inc. Pharmaceutical grade garlic
US6206916B1 (en) * 1998-04-15 2001-03-27 Joseph G. Furst Coated intraluminal graft
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2449264A (en) * 2007-05-15 2008-11-19 Chameleon Biosurfaces Ltd A coated medical device
WO2008139200A3 (en) * 2007-05-15 2009-10-29 Chameleon Biosurfaces Limited Polymer coatings on medical devices
US8343212B2 (en) 2007-05-15 2013-01-01 Biotectix, LLC Polymer coatings on medical devices
WO2012076016A1 (en) * 2010-12-08 2012-06-14 Danmarks Tekniske Universitet Process for the manufacture of ajoene derivatives
CN103328441A (en) * 2010-12-08 2013-09-25 丹麦技术大学 Process for the manufacture of ajoene derivatives
JP2014508719A (en) * 2010-12-08 2014-04-10 ダンマークス テクニスク ユニバーシテット Process for producing ajoene derivatives
EP3020397A3 (en) * 2010-12-08 2016-08-17 Danmarks Tekniske Universitet Process for the manufacture of ajoene derivatives
CN103328441B (en) * 2010-12-08 2016-08-31 丹麦技术大学 The preparation method of 4,5,9-trithiadodeca-1,6,11-triene 9-oxide. derivant
JP2017061525A (en) * 2010-12-08 2017-03-30 ダンマークス テクニスク ユニバーシテット Process for the manufacture of ajoene derivatives
AU2016203651B2 (en) * 2010-12-08 2017-06-01 Danmarks Tekniske Universitet Process for the manufacture of ajoene derivatives
US10603289B2 (en) 2010-12-08 2020-03-31 Danmarks Tekniske Universitet Process for the manufacture of ajoene derivatives

Also Published As

Publication number Publication date
GB0120887D0 (en) 2001-10-17
WO2003018080A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
RU2360646C2 (en) Endoluminal prosthesis containing medical agent
US7323189B2 (en) Liquid and low melting coatings for stents
EP1362603B1 (en) Coated stent for release of active agents
CA2704947C (en) Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity
US7144419B2 (en) Drug-polymer coated stent with blended phenoxy and styrenic block copolymers
US8518097B2 (en) Plasticized stent coatings
JP2004531331A (en) Drug administration device
KR20030005068A (en) Stent
JPH0956807A (en) Stent adhered and coated with medicine and its production
CN101631514A (en) Multi-drug eluting coronary stent for percutaneous coronary intervention
EP2178579A2 (en) Drug eluting medical device and method
JP2008253707A (en) Drug-eluting stent
KR20110009055A (en) Coatings for Medical Devices with Antithrombogenic Conjugates
Steffel et al. Biological effects of drug-eluting stents in the coronary circulation
US20090112307A1 (en) Stent having a base body of a bioinert metallic implant material
JP2022078154A (en) Drug-eluting stent
WO2003018082A2 (en) Local drug delivery system in coronary stents
US9452243B2 (en) Implant comprising an active-agent-containing coating covering the implant at least in sections
US20160157483A1 (en) Composition for the cleaning and protection of technical surfaces
JP2021511891A (en) Methods and devices for reducing vascular smooth muscle cell proliferation
JP2009521961A (en) Coronary stent releasing drug composition for restenosis prevention treatment and its assembly process
US20220241467A1 (en) Stent with immediately removeable coating
Das et al. Current Research Journal of Pharmaceutical and Allied Sciences
CN1306917C (en) A stent for preventing/treating intravascular restenosis through a composite mechanism of action
Sorop et al. Neointimal hyperplasia and endothelial function after percutaneous coronary intervention

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VC YU ZA ZM ZW GH GM KE LS MW MZ SL SZ TZ UG ZM ZW

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
NENP Non-entry into the national phase in:

Ref country code: JP